Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y., Sep 17, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue...
DEERFIELD, IL, September 15, 2009 – Astellas Pharma US, Inc. today announced the winners of the Astellas Ride of a LifetimeSM 2010 contest. The contest asked transplant recipients to submit...
Chicago Mayor Richard M. Daley honored Astellas Pharma US, Inc. and two other Chicagoland companies on Aug. 14 at a ceremony in downtown Chicago with an award for their exemplary learning and...
Read more about Chicago Mayor Honors Astellas' Excellence in Learning, Development
Astellas Pharma US, Inc. ("Astellas") announced today an update regarding the status of the request for emergency relief and preliminary injunction from the U.S. Food and Drug Administration's...
In a ceremony recognizing "Chicago's 101 Best and Brightest Companies to Work For," Astellas Pharma US, Inc. won an Elite award for employee engagement and commitment by the National Association...
Unique needs of transplant patients require special care to preserve their gift of life Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has...
Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache SAN DIEGO, CA, and DEERFIELD, IL (August 3, 2009): Zogenix, Inc. (“Zogenix”), a privately held...
MELVILLE, N.Y., Aug 01, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib)...
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jul 13, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. today announced that SATURN, a pivotal Phase III study of...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 6, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
MELVILLE, N.Y., Jun 15, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
DEERFIELD, IL, June 4, 2009 – Astellas Pharma Global Development (“APGD”), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Betsy Garofalo has been hired...
Read more about Astellas Adds CNS Therapy Area Leader to Global R&D Team
DEERFIELD, IL, June 1, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Dan Dunham as the vice president of compliance. Dunham will be responsible for governance of the compliance...
Read more about Astellas Hires New Vice President of Compliance
Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy ORLANDO, Fla., May 30, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that...
Deerfield, IL (May 28, 2009) – The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf® (tacrolimus) in conjunction with mycophenolate...
DEERFIELD, IL, May 28, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Walt Johnston as vice president of marketing. Reporting directly to Patrick Shea, senior vice president of...
Read more about Astellas Announces New Vice President of Marketing
Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma Patients with an EGFR Mutation Achieved a 10 Fold Increase in the Time Patients Live...
Arginine vasopressin (AVP) receptor antagonist now available in new premixed formulation DEERFIELD, Illinois, April 1, 2009 — Astellas Pharma US, Inc. today announced the commercial availability...
Company continues path toward goal to become global category leader DEERFIELD, IL, April 1, 2009 – Astellas Pharma US, Inc. (“Astellas”) announced today Seigo Kashii, has been appointed...
Roche Submits Marketing Authorization Application for Approval of Tarceva as a First-line Maintenance Therapy in Europe MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19,...
MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 10, 2009-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals...
Read more about OSI Pharmaceuticals Announces Notification of ANDA Filing for Tarceva
Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy MELVILLE, N.Y.--(BUSINESS WIRE)-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its U.S....
MELVILLE, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today's announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...
First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment SOUTH SAN FRANCISCO, Calif. & MELVILLE,...
Arginine vasopressin (AVP) receptor antagonist now approved in single-use premixed formulation DEERFIELD, Illinois, October 22, 2008 — Astellas Pharma US, Inc. today announced that the U.S. Food...
Follow U.S. news
